Overview Dividends

(GLPG) Galapagos - Ratings and Ratios

Exchange: NASDAQ • Country: Belgium • Currency: USD • Type: Common Stock • ISIN: US36315X1019

Medicine, Oncology, Immunology, CAR-T, Biotech

GLPG EPS (Earnings per Share)

EPS Growth (3Y CAGR): 314.42%
EPS Trend (3Y Correlation): -20.7%

GLPG Revenue

Revenue Growth (3Y CAGR): -10.01%
Revenue Trend (3Y Correlation): 9.1%

Risk via 10d forecast
Volatility	31.3%
Value at Risk 5%th	45.9%

Reward
Sharpe Ratio	0.51
Alpha	14.39

Character
Hurst Exponent	0.235
Beta	-0.050

Drawdowns 3y
Max DD	52.73%
Mean DD	30.06%

Description: GLPG Galapagos November 10, 2025

Galapagos NV (NASDAQ:GLPG) is a Belgium-based biotech focused on developing small-molecule and cell-therapy candidates for oncology and immunology, primarily targeting the U.S. and European markets.

Its current pipeline includes four point-of-care CAR-T programs: GLPG5101 (CD19 CAR-T for relapsed/refractory non-Hodgkin lymphoma), GLPG5201 (CD19 CAR-T for relapsed/refractory chronic lymphocytic leukemia), GLPG5301 (BCMA CAR-T for relapsed/refractory multiple myeloma), and GLPG3667, which has completed a Phase 1b trial. All CAR-T candidates are in Phase 1/2, indicating early-stage clinical risk but also the potential for rapid value creation if efficacy and safety benchmarks are met.

Strategic collaborations with Gilead Sciences and AbbVie provide non-dilutive funding and development expertise; to date, Galapagos has received over €300 million in upfront and milestone payments, which helps offset its cash burn of roughly €150 million per year (FY 2024). The company’s market capitalization is approximately $7 billion, giving a price-to-cash-burn multiple of about 4.5×, modest relative to the broader CAR-T sector where peers trade at 6–10×.

Key sector drivers that could amplify Galapagos’ upside include the projected CAGR of ~15 % for the global CAR-T market through 2030 and increasing reimbursement willingness for point-of-care manufacturing, which reduces logistics costs and expands access in community hospitals.

For a deeper quantitative assessment, you may want to explore ValueRay’s detailed valuation models for GLPG.

GLPG Stock Overview

Market Cap in USD	2,078m
Sub-Industry	Biotechnology
IPO / Inception	2005-05-06
Return 12m vs S&P 500	-0.65%
Analyst Rating	2.50 of 5

GLPG Dividends

Currently no dividends paid

GLPG Growth Ratios

CAGR	-9.06%
CAGR/Max DD Calmar Ratio	-0.17
CAGR/Mean DD Pain Ratio	-0.30
Current Volume	200.9k
Average Volume	177.9k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-436.0m TTM) > 0 and > 6% of Revenue (6% = 17.2m TTM)

FCFTA -0.07 (>2.0%) and ΔFCFTA 2.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1145 % (prev 1338 %; Δ -193.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.07 (>3.0%) and CFO -269.4m > Net Income -436.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (65.9m) change vs 12m ago -0.08% (target <= -2.0% for YES)

Gross Margin -38.90% (prev 56.80%; Δ -95.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 6.91% (prev 5.75%; Δ 1.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -4.28 (EBITDA TTM -346.9m / Interest Expense TTM 24.4m) >= 6 (WARN >= 3)

Altman Z'' 4.23

(A) 0.80 = (Total Current Assets 3.72b - Total Current Liabilities 430.7m) / Total Assets 4.13b

(B) -0.16 = Retained Earnings (Balance) -678.8m / Total Assets 4.13b

(D) -0.27 = Book Value of Equity -340.8m / Total Liabilities 1.25b

Total Rating: 4.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.52

1. Piotroski 0.50pt = -4.50

2. FCF Yield 16.15% = 5.0

3. FCF Margin data missing

4. Debt/Equity 0.00 = 2.50

5. Debt/Ebitda 0.19 = 2.47

6. ROIC - WACC (= -9.68)% = -12.10

7. RoE -15.62% = -2.50

8. Rev. Trend 9.13% = 0.68

9. EPS Trend -20.71% = -1.04

What is the price of GLPG shares?

As of November 10, 2025, the stock is trading at USD 31.53 with a total of 200,896 shares traded.
Over the past week, the price has changed by +1.78%, over one month by -7.32%, over three months by +0.10% and over the past year by +12.69%.

Is Galapagos a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Galapagos (NASDAQ:GLPG) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.52 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GLPG is around 27.49 USD . This means that GLPG is currently overvalued and has a potential downside of -12.81%.

Is GLPG a buy, sell or hold?

Galapagos has received a consensus analysts rating of 2.50. Therefor, it is recommend to sell GLPG.

Strong Buy: 0
Buy: 0
Hold: 4
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the GLPG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	30.6	-3%
Analysts Target Price	30.6	-3%
ValueRay Target Price	30	-4.8%

GLPG Fundamental Data Overview November 10, 2025

Market Cap EUR = 1.80b (2.08b USD * 0.865 USD.EUR)
P/E Forward = 344.8276
P/S = 7.2415
P/B = 0.7621
Beta = -0.05
Revenue TTM = 286.9m EUR
EBIT TTM = -104.4m EUR
EBITDA TTM = -346.9m EUR
Long Term Debt = 11.7m EUR (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 2.04m EUR (from shortTermDebt, last quarter)
Debt = 8.81m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -66.9m EUR (from netDebt column, last quarter)
Enterprise Value = -1.78b EUR (1.80b + Debt 8.81m - CCE 3.58b)
Interest Coverage Ratio = -4.28 (Ebit TTM -104.4m / Interest Expense TTM 24.4m)
FCF Yield = 16.15% (FCF TTM -287.0m / Enterprise Value -1.78b)
FCF Margin = -100.0% (FCF TTM -287.0m / Revenue TTM 286.9m)
Net Margin = -151.9% (Net Income TTM -436.0m / Revenue TTM 286.9m)
Gross Margin = -38.90% ((Revenue TTM 286.9m - Cost of Revenue TTM 398.5m) / Revenue TTM)
Gross Margin QoQ = -275.5% (prev 92.79%)
Tobins Q-Ratio = -0.43 (set to none) (Enterprise Value -1.78b / Total Assets 4.13b)
Interest Expense / Debt = 266.8% (Interest Expense 23.5m / Debt 8.81m)
Taxrate = 7.90% (-17.5m / -221.5m)
NOPAT = -96.1m (EBIT -104.4m * (1 - 7.90%)) [loss with tax shield]
Current Ratio = 8.63 (Total Current Assets 3.72b / Total Current Liabilities 430.7m)
Debt / Equity = 0.00 (Debt 8.81m / totalStockholderEquity, last quarter 2.88b)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -66.9m / EBITDA -346.9m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -66.9m / FCF TTM -287.0m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.56% (Net Income -436.0m / Total Assets 4.13b)
RoE = -15.62% (Net Income TTM -436.0m / Total Stockholder Equity 2.79b)
RoCE = -3.72% (EBIT -104.4m / Capital Employed (Equity 2.79b + L.T.Debt 11.7m))
RoIC = -3.48% (negative operating profit) (NOPAT -96.1m / Invested Capital 2.76b)
WACC = 6.20% (E(1.80b)/V(1.81b) * Re(6.23%) + (debt cost/tax rate unavailable))
Discount Rate = 6.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
Fair Price DCF = unknown (Cash Flow -287.0m)
EPS Correlation: -20.71 | EPS CAGR: 314.4% | SUE: 0.16 | # QB: 0
Revenue Correlation: 9.13 | Revenue CAGR: -10.01% | SUE: 0.02 | # QB: 0

Additional Sources for GLPG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle